Loading…
ICCC
Immucell Corp
NASDAQ· Healthcare· Biotechnology· CUSIP 452525306
$9.94-0.80%Price as of Aug 29, 18:36 UTC · updated once a day, after the close
Key metrics
- Market cap
- $90.28M
- P/E
- 142.0x
- Forward P/E
- —
- P/B
- 2.9x
- Dividend yield
- —
- Payout
- —
- EPS
- $0.07
- ROE
- 2.57%
- Profit margin
- 2.57%
- Revenue growth
- +11.50%
- Beta
- 0.57
- 52-week high
- $12.10
- 52-week low
- $4.52
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +12.8% over 5Y.
today you would have $1,060.36▲ +6.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $6.15 | $5.15 | $5.09 | $6.10 | $8.00 | $5.95 | $5.15 | $7.05 | $8.79 | $5.95 | $7.54 | $4.86 | $4.27 | $4.00 | $4.65 | $3.20 | $3.71 | |
Fair price, seven ways
Seven formulas applied to what the company reported. None of them predicts a price — each answers what the stock would be worth if its assumption held. The assumption is printed next to every number, because it is the assumption that produces the result.
Earnings
$2.33
Square root of 22.5 × earnings × book value — the two ceilings Graham proposed. Blind to intangibles, so it undervalues software and brands.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
$1.57
Median P/E of 22.4 among peers in the sector.
Earnings
$5.47
Median P/E of 78.2 across the years on record for this company itself. Answers whether it is cheap against its own past, which a whole sector trading low cannot flatter.
Cash flow
$1.63
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$5.94
Sector median of 13.3x operating profit, less net debt. Sees the business before its financing, so debt does not distort the comparison. Banks have no EBITDA — interest is their revenue, not a cost.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| DWTXDogwood Therapeutics, Inc. | $2.65 | 1.2x | 1.3x | — | -47.77% | $90.08M |
| RLYBRallybio Corp | $16.86 | 2.1x | 0.9x | — | 64.86% | $89.57M |
| ACRVAcrivon Therapeutics, Inc. | $2.15 | — | 1.1x | — | -64.63% | $92.13M |
| ATRAAtara Biotherapeutics, Inc. | $8.81 |
About the company
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
- 73
- Portland, United States
Company description provided by Yahoo Finance.